Generate Biomedicines stock rises for a second session, extending gains after a near 10% advance yesterday.
Shares of AI-driven drug developer Generate Biomedicines climbed 12% to $19.81, adding $2.09 in mid-afternoon trading. The move builds on a nearly 10% gain from the prior session, marking a two-day rally for the stock.
The company, which uses artificial intelligence for drug discovery, has seen renewed investor interest but has not disclosed specific catalysts for the recent surge. Trading volume and broader sector trends are being monitored for further signals.
No immediate market reaction data was provided, though the stock’s momentum reflects growing appetite for biotech innovation plays.